Dupilumab reduced impact of severe exacerbations on lung function in patients with moderate-to-severe type 2 asthma.
FEV1
dupilumab
severe exacerbations
type 2 biomarkers
Journal
Allergy
ISSN: 1398-9995
Titre abrégé: Allergy
Pays: Denmark
ID NLM: 7804028
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
revised:
10
06
2022
received:
21
12
2021
accepted:
05
07
2022
pubmed:
29
7
2022
medline:
30
12
2022
entrez:
28
7
2022
Statut:
ppublish
Résumé
Severe asthma exacerbations increase the risk of accelerated lung function decline. This analysis examined the effect of dupilumab on forced expiratory volume in 1 s (FEV Changes from baseline in pre- and post-bronchodilator (BD) FEV In exacerbators and non-exacerbators, dupilumab increased pre-BD FEV Dupilumab treatment led to improvements in lung function independent of exacerbations and appeared to reduce the impact of exacerbations on lung function in patients who experienced a severe exacerbation during the study.
Sections du résumé
BACKGROUND
Severe asthma exacerbations increase the risk of accelerated lung function decline. This analysis examined the effect of dupilumab on forced expiratory volume in 1 s (FEV
METHODS
Changes from baseline in pre- and post-bronchodilator (BD) FEV
RESULTS
In exacerbators and non-exacerbators, dupilumab increased pre-BD FEV
CONCLUSION
Dupilumab treatment led to improvements in lung function independent of exacerbations and appeared to reduce the impact of exacerbations on lung function in patients who experienced a severe exacerbation during the study.
Identifiants
pubmed: 35899469
doi: 10.1111/all.15456
pmc: PMC10087924
doi:
Substances chimiques
dupilumab
420K487FSG
Antibodies, Monoclonal, Humanized
0
Biomarkers
0
Banques de données
ClinicalTrials.gov
['NCT02414854']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
233-243Informations de copyright
© 2022 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
Références
Chest. 2007 Dec;132(6):1882-9
pubmed: 18079222
Am J Respir Crit Care Med. 2009 Jan 1;179(1):19-24
pubmed: 18990678
Clin Exp Allergy. 2014 Feb;44(2):212-21
pubmed: 24447083
Ann Am Thorac Soc. 2020 Mar;17(3):302-312
pubmed: 31800292
N Engl J Med. 1998 Oct 22;339(17):1194-200
pubmed: 9780339
Expert Rev Clin Immunol. 2017 May;13(5):425-437
pubmed: 28277826
J Allergy Clin Immunol Pract. 2018 May - Jun;6(3):980-986.e1
pubmed: 29398640
J Allergy Clin Immunol. 2015 Oct;136(4):1125-7.e4
pubmed: 26104221
Allergy. 2023 Jan;78(1):233-243
pubmed: 35899469
Pharmacol Res. 2020 Oct;160:105189
pubmed: 32911071
Proc Natl Acad Sci U S A. 2014 Apr 8;111(14):5147-52
pubmed: 24706858
N Engl J Med. 2018 Jun 28;378(26):2486-2496
pubmed: 29782217
Allergy. 2020 May;75(5):1188-1204
pubmed: 31838750
Am J Respir Crit Care Med. 2017 Feb 1;195(3):302-313
pubmed: 27556234
Eur Respir J. 2018 Apr 19;51(4):
pubmed: 29563173
Lancet Respir Med. 2021 Oct;9(10):1165-1173
pubmed: 34181876
Proc Natl Acad Sci U S A. 2014 Apr 8;111(14):5153-8
pubmed: 24706856
Chest. 2021 Feb;159(2):496-506
pubmed: 32882249
Nat Rev Drug Discov. 2016 Jan;15(1):35-50
pubmed: 26471366
Expert Rev Respir Med. 2016 Jun;10(6):607-17
pubmed: 27058452
Eur Respir J. 2018 Feb 14;51(2):
pubmed: 29444915
Lancet Respir Med. 2021 Oct;9(10):1174-1184
pubmed: 33971168
Eur Respir J. 2020 Mar 5;55(3):
pubmed: 31831580
N Engl J Med. 2018 Jun 28;378(26):2475-2485
pubmed: 29782224
N Engl J Med. 2003 Oct 9;349(15):1414-22
pubmed: 14534334
Eur Respir J. 2007 Sep;30(3):452-6
pubmed: 17537763